Pulmatrix has dosed the first patient in a Phase I/Ib clinical trial of Pulmazole (PUR1900) for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

The trial includes healthy subjects and patients with mild to moderate stable asthma.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will also feature single ascending dose (SAD) and multiple ascending dose (MAD) arms in normal healthy volunteers (NHV) to evaluate safety, tolerability, and pharmacokinetics (PK).

In addition, a third study arm will be conducted to assess safety and tolerability in patients with mild to moderate stable asthma. It will comprise PK analysis of itraconazole levels in the blood and sputum following administration of a single dose of oral itraconazole or Pulmazole in a crossover study design.

“Pulmazole can provide higher lung exposure and lower systemic exposure than oral Sporanox.”

The trial expects to include up to 42 subjects in the SAD/MAD evaluation in NHV and 16 asthmatic patients in the crossover study. The company expects that top-line results will be available in mid-2018.

Pulmatrix chief medical officer Jim Roach said: “In addition to generating the requisite safety and tolerability data from this study to advance dosing of Pulmazole into asthmatic patients with ABPA, we anticipate that the collective pharmacokinetic data obtained in Phase I will further corroborate the key PK preclinical findings reported last week at the eighth Advances Against Aspergillosis Conference in Lisbon, Portugal, namely, that Pulmazole can provide higher lung exposure and lower systemic exposure than oral Sporanox.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pulmatrix’s Pulmazole (PUR1900) is an inhaled iSPERSE dry powder formulation of the anti-fungal drug itraconazole designed to treat ABPA in asthma patients.